Biochemical and Biophysical Research Communications
Characterization of γδ regulatory T cells from peripheral blood in patients with multiple myeloma
Introduction
Multiple myeloma (MM) is one kind of malignant tumor of plasma cell disorder [1], [2]. MM patients are often complicated with anemia, higher M-protein, bone lesions and organ injury [3]. γδT cells can promote immune response against myeloma through their direct cytotoxic activity and through stimulating or regulating biological functions of other types of cells such as cytotoxic CD8+ T cells [4], [5]. However, recent studies suggest that tumor infiltrating γδ T cells may be a good prognostic factor of cancer because the presence of these cells in tumor microenvironment was correlated with poor prognosis for breast and colon cancer patients [6], [7]. The expansion of regulatory γδT cells (γδTreg cells) in patients with nasopharyngeal, renal and gastric cancer has been confirmed [8]. However, the number and the potential role of γδTreg cells in supressing anti-tumor immune responses in MM patients remain largely unclear.
In this study, we measured the levels of γδTreg cells in recently diagnosed MM patients, relapsed MM patients and healthy control volunteers. Additionally, we tried to determined the relationship between clinical features of MM and γδTreg cells. Furthermore, we detected the expression of immunoregulatorory-associated molecules in peripheral blood from patients with MM and healthy donors.
Section snippets
Subjects
Total 10 normal volunteers (Table 1), 11 remission (CR, VGPR and PR) patients with myeloma (Table 2) and 7 new-onset or relapse patients with myeloma (Table 3) were enrolled and their peripheral blood cells were applied for the assay in vitro and the isolation of γδT cells. Obtained written informed consent was necessary from each subject before being enrolled in our study, and approved protocol by Ethics Committee of Nanfang Medical University was indicated.
Isolation and culture of γδT cells
γδT cells were purified from PBMCs
Quantitative RT-PCR
Total RNA was isolated using RNA isolation kit following the manufacturer's instructions (Qiagen, Germantown, MD, USA). RNA was reverse transcribed using the SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). cDNA was analyzed using a quantitative PCR (qPCR) with aCFX Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The sequences of primers for immunoregulatory-associated molecules were shown in Table 5.The relative RNA levels were measured by normalizing with β2
The γδT cells numbers and percentages of lymphocytes among healthy control, remission myeloma patients and new onset/relapse myeloma patients
The percentages of γδ T cells among lymphocytes was 3.09± 0.11% (n = 10) and the numbers of γδ T cells were 43.1 ± 2.86 per 1 μl of PB in healthy controls. The percentages of γδ T cells among lymphocytes was 2.66± 0.15% (n = 11) and numbers of γδ T cells were 36.30 ± 2.34 per 1 μl of PB in remission myeloma patients, significantly reduced compared to healthy controls (P < 0.05). The percentages of γδ T cells among lymphocytes were 1.58± 0.12% (n = 7) of lymphocytes and numbers ofγδ T cells were
Discussion
Human γδT cells are immune cells that harbor specialized T-cell receptors (TCRs) which can recognize nonpeptidic phosphorylated metabolites of isoprenoid biosynthesis produced by stressed cells and microorganisms. γδT cells represent only a fraction of T cells found in peripheral blood and play important role in immuno response to infections and tumors [4], [5].
γδ T cells promote immune response against various tumors such as myeloma, colon, breast, lymphoma, and prostate cancer directly by
Conflict of interest statement
We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in the manuscript entitled “Characterization of γδ regulatory T cells from peripheral blood in patients with multiple myeloma”.
Acknowledgement
This study was supported by grants from Medical Science and Technology Project of Zhejiang Province (No. 2014KYA132); Wenzhou City Science and Technology Projects (No. Y20140072); Natural Science Foundation of Zhejiang Province (No. Q16H080007)and Grant of National Natural Science Foundation (No.81600167).
References (25)
- et al.
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Blood
(2016) - et al.
Identification and characterization of foxp3(+) gammadelta t cells in mouse and human
Immunol. Lett.
(2009) - et al.
TRGV and TRDV repertoire distribution and clonality of T cells from umbilical cord blood
Transpl. Immunol.
(2009 Jan) - et al.
Human vdelta1 gamma-delta t cells exert potent specific cytotoxicity against primary multiple myeloma cells
Cytotherapy
(2012) - et al.
T lymphocytes engineered to express a cd16-chimeric antigen receptor redirect t-cell immune responses against immunoglobulin g-opsonized target cells
Cytotherapy
(2016) - et al.
Avidity of human t cell receptor engineered cd4(+) t cells drives t-helper differentiation fate
Cell. Immunol.
(2016) - et al.
Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
Oncotarget
(2015) - et al.
Dexamethasone treatment promotes bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
Leukemia
(2016) - et al.
Effector gammadelta t cells and tumor cells as immune targets of zoledronic acid in multiple myeloma
Leukemia
(2005) - et al.
Zoledronic acid-induced expansion of gammadelta t cells from early-stage breast cancer patients: effect of il-18 on helper nk cells
Cancer Immunol. Immunother. CII
(2013)